Background: OCT1002 is a unidirectional hypoxia-activated prodrug (uHAP) OCT1002 that can target hypoxic tumor cells. Hypoxia is a common feature in prostate tumors and is known to drive disease progression and metastasis. It is, therefore, a rational therapeutic strategy to directly target hypoxic tumor cells in an attempt to improve treatment for this disease. Here we tested OCT1002 alone and in combination with standard-of-care agents in hypoxic models of castrate-resistant prostate cancer (CRPC).
genetic instability, 10 gene amplification, 11 endothelial-to-mesenchymal transition (EMT) 12, 13 and selection of cells with diminished apoptotic potential and a greater invasive potential. 14, 15 It is, therefore, a viable therapeutic strategy to directly target hypoxic tumor cells in an attempt to improve treatment, meaning hypoxic targeting is likely to be a key part of precision medicine for prostate cancer. 16, 17 One approach to blocking the influence of hypoxic tumor cells is to directly target this sub-population with a hypoxia-activated prodrug (HAP). HAPs are compounds that are designed to be reduced to an active, toxic form in cells when oxygen levels are very low. 18, 19 However, conventional HAPs (eg, tirapazamine, TH302, PR-104) are reduced in single-electron reduction steps, a reversible process that can redox cycle producing reactive oxygen in normoxic tissue. 16 In contrast, alkylaminoanthraquinone-di-N-oxides are prodrugs that have a different mechanism of activation. These aliphatic N-oxides are reduced through an obligate two-electron reduction. This results in oxygen atom transfer which under hypoxic conditions results in irreversible formation of a stable anti-proliferative agent and water.
For this reason, our previous work has focused on AQ4N 20 and its more recently described deuterated analogue OCT1002 (OncoTherics Ltd). 21, 22 These unidirectional HAPS (uHAPs) are reduced in hypoxia to the metabolically stable reduction products (AQ4 and OCT1001, respectively). Studies with AQ4N and OCT1002 show that hypoxiamediated reduction results in a product with high affinity for DNA and targeting of topoisomerase II, 23, 24 which can effect a long-term inhibition of both DNA replication and G2/M cell transition. 25, 26 Previously we have shown that OCT1002 kills hypoxic prostate cancer cells in vitro and in vivo. 21 We provided the first evidence that OCT1002 has a hypoxia-dependent anti-tumor effect in androgensensitive LNCaP prostate tumor xenografts and the effect can be markedly enhanced when combined with daily bicalutamide administration, a drug which targets the androgen receptor (AR). This is consistent with previous studies in the same model, which showed that AQ4N can block re-oxygenation that occurs during prolonged (>14 days) treatment with daily bicalutamide. 27 We have also shown that single-modality hormone treatment drives development of more malignant tumors, a consequence of reduced vascularization and oxygenation (days 1-14) followed by a revascularization and reoxygenation over the next 14 days. This was accompanied by a cascade of molecular and phenotypic changes that included evidence of EMT and increased metastasis to the lungs within 4 weeks. 13, 27 The novel analogue OCT1002 caused similar effects in LNCaP xenografts and we also showed that it could block significantly the molecular changes caused by bicalutamide alone, 21 thereby demonstrating that detrimental hypoxia-induced cellular responses can be effectively blocked.
To further demonstrate the potential of OCT1002, it is important to test its effect in other xenograft models to ensure this is not a cellline specific result. In particular, it would be instructive to see its impact on androgen-independent prostate tumor cells, since there is a clear clinical need for strategies that can improve the treatment of castrateresistant prostate cancer (CRPC). Therefore, the current study has been designed to evaluate the effect of OCT1002 on CRPC tumor growth using murine PC3 xenograft and dorsal skin fold (DSF) models. xenograft, was implanted onto surgically exposed panniculus carnosus muscle within the window, washed with saline and covered with a plastic cover slip. After surgery mice were given a topical prophylactic antibiotic (Chloramphenicol; Martindale Pharmaceuticals, UK). Tumors were allowed to vascularize for 7 days following surgery and then randomly assigned to treatment groups, this was designated as day 0, and assigned to treatment groups with drug concentrations as described above. Tumor vasculature was then imaged on days 0, 7, 14, 21 using a stereomicroscope. Image analysis was carried out using Touptek software (Touptek Photonics, China). All surgical procedures were performed under aseptic conditions and the body temperature of animals was kept constant using heated pads.
| Statistical analysis
Data from in vitro and in vivo studies were analyzed using a two-tailed student's t-test unless otherwise indicated. All statistical analysis was carried out using the Prism 5.0 software (GraphPad). Differences between points were deemed statistically significant with a P < 0.05 (95% confidence interval). OCT1002 treatment resulted in a significant reduction in the mean vessel area covered on days 14 and 21, while abiraterone resulted in a significant vessel reduction at days 7, 14, and 21. Docetaxel significantly reduced vasculature compared to vehicle on day 7 and 14, but by day 21 tumor vasculature was restored to levels similar to that displayed in control tumors. Cabazitaxel treatment showed a trend toward reduced vasculature compared to control but these measurements did not reach significance.
| Effect of drug combinations on PC3 tumor growth and vasculature
Each of the clinically approved chemotherapy drugs was then given in combination with OCT1002 on day 1. In the PC3 xenograft model, no marked advantage was observed in the combinations, although it was noted that cabazitaxel was better tolerated when the mice were treated with cabazitaxel in combination with OCT1002
( Figures 3A-3C ). However, when tumors were analyzed in the DSF model, OCT1002 caused a significant growth reduction when used in combination with the other drugs, compared to single treatment ( Figures 4A-4C ). This effect was most marked when OCT1002 was used in combination with cabazitaxel and docetaxel ( Figures 4B and 4C ).
When the mean vessel density was measured in the PC3 DSF model it was clear that the drug combinations also had an effect on tumor vasculature. When OCT1002 was combined with abiraterone the vascular density was further reduced on day 14 and 21, compared to OCT1002 alone ( Figure 5A ). OCT1002 appeared to cause some further reduction on the vasculature in combination with cabazitaxel, though it only reached significance on day 14 ( Figure 5B ). Combining OCT1002 with docetaxel resulted in significantly reduced vasculature at day 14 and 21 compared to either drug used singly ( Figure 5C ).
| DISCUSSION
Improving treatment of CRPC remains a major challenge for clinicians.
Current chemotherapy includes cytotoxic agents such as docetaxel and cabazitaxel, or drugs targeting AR axis signalling, such as enzalutamide and abiraterone. 32 However, drug resistance to these Figure S1 ) to corroborate cell-line analysis from our previous study. 21 Having demonstrated the effect of OCT1002 on PC3 cells in vitro, we proceeded to use PC3 cells in murine models in vivo. In our previous work, we measured the oxygen levels in LNCaP and 22Rv1 tumors in SCID mice and found that each untreated tumor type had an intrinsic level of oxygenation that was specific and consistently reproducible. 13, 21 Here, we demonstrated that PC3 tumors grown in nude mice are considerably more hypoxic than LNCaP and 22Rv1 tumors ( Figure 1A ). Based on our experience of tumor xenograft models, we propose that the intrinsic hypoxic status of the tumors is determined by several inter-dependent factors. Clearly a major factor will be the extent of the vascular network that develops in vivo, which can subsequently change in response to anti-tumor treatments. 13, 21 Linked to this, these prostate tumor cell lines have a varying genetic background and exhibit considerable differences in a number of signalling pathways that affect both metabolism and the cells' ability to develop a functioning vascular network. 34 Thus, it is not surprising that they exhibit differing levels of vasculature and oxygenation in the tumors grown in vivo. Furthermore, it is likely that tumor hypoxia will vary depending on the mouse strain used in these models. For example, we get consistent results for each model that we have used, but interestingly LNCaP tumors are more hypoxic when grown in SCIDs than nudes, suggesting the specific characteristics of the growth environment plays a role too. It therefore appears that oxygenation of tumors in vivo is determined by different over-lapping physiological and molecular influences, which will be important to our understanding of tumor biology in the treatment responses of preclinical models.
Indeed, many of these factors are likely to influence treatment responses for CRPC.
The intrinsically low oxygen levels in PC3 tumors suggested that OCT1002 should certainly be activated in these tumors. Indeed, it
should be noted that all three of these xenograft tumors have oxygen levels which are well below that of normal prostate tissue ∼4%. The range demonstrated in the mouse tumor xenografts is consistent with oxygenation levels exhibited by human prostate tumors, making them a clinically relevant model for testing OCT1002. 6 We first showed a lack of OCT1002 systemic toxicity in this PC3 xenograft model, as measured by mouse body weight retention ( Figure 1B ). This is consistent with OCT1002 acting as a prodrug which is inactive in normal tissues. We then proceeded to test its ability to control tumor growth, using three approved chemotherapy drugs for FIGURE 4 Effect of OCT1002 in combination with standard prostate cancer chemotherapeutics on PC3 tumor growth in dorsal skin fold model. The DSF model was initiated as described in Figure 2 . OCT1002 (30 mg/kg; day 1) was administered alone or combination with (A) abiraterone (B) cabazitaxel, or (C) docetaxel at the respective doses described in Figure 2 . Images were taken once per week. Tumor surface area data is expressed as the mean ± SEM (n ≥ 3) relative to control at each time point. In each graph student t-test was used to compare combination to OCT1002 alone (P-values: *P < 0.05, **P < 0.01, ***P < 0.001) and to respective standard drug monotherapy (P-values: P < 0.05,^^P < 0.01,^^^P < 0.001)
FIGURE 5
Effect of OCT1002 in combination with standard prostate cancer chemotherapeutics on PC3 tumor vascularization in dorsal skin fold model. The DSF model and dosing as described in Figure 4 . Tumor vessel coverage data are expressed as the mean ± SEM (n ≥ 3) relative to control at each time point. In each graph student t-test was used to compare combination to OCT1002 alone (P-values: *P < 0.05, **P < 0.01, ***P < 0.001) and to respective standard drug monotherapy (P-values:^P < 0.05,^^P < 0.01,^^^P < 0.001)
comparison purposes. All drugs demonstrated significant tumor growth control at day 28 compared to vehicle treatment. Cabazitaxel (5 mg/kg; 1× week) had some anti-tumor efficacy, but was also the most toxic to the mice. Docetaxel (10 mg/kg; 2× week) showed a similar inhibition of tumor growth but was better tolerated.
Abiraterone (98 mg/kg; daily) exhibited the best tumor growth control.
Comparing these drugs with OCT1002, we found it particularly noteworthy that a single, low dose of OCT1002 (30 mg/kg; administered on day 1) demonstrated similar tumor growth control to both cabazitaxel and docetaxel ( Figure 1C ). As observed above, this may be because PC3 tumors are extremely hypoxic and thus particularly susceptible to OCT1002. This also underlines the potential success that OCT1002 may have in the clinic if used in patients identified to have hypoxic tumors, either by molecular or physical biomarkers.
Encouragingly, PET-based imaging techniques have been established that can be used to quantify the hypoxic fraction, 35 including an ongoing clinical trial (NCT01567800), which could identify those patients most likely to benefit from OCT1002. For example, CRPC patients predicted to have worse outcome on enzalutamide or abiraterone 36 could be offered a new treatment option based on use of OCT1002.
The persistent, long-lasting effect of OCT1002 was further demonstrated when we stopped treatment with the three approved drugs at day 14 and compared tumor regrowth over the next 28 days to the OCT1002 treatment group, which had received a single dose on day
1. This single, early dose of OCT1002 showed a similar ability to inhibit tumor regrowth as abiraterone and docetaxel ( Figures 1D and 1E ). It was markedly better than cabazitaxel treatment, which proved quite toxic to mice in this experiment, to the extent that mice had to be prematurely sacrificed. This demonstrates the unique uHAP properties of OCT1002, in that a long-lasting effect is achieved due to the irreversible activation within hypoxic cells to the toxic reduction product OCT1001. We propose this selective targeting prevents the ability of hypoxia-resistant cells to re-establish the tumor as quickly.
Since our previous work had identified the importance of drug effects on LNCaP tumor vasculature, we wanted to extend this to other tumor models and therefore examined how OCT1002 impacted upon PC3 tumor vasculature in vivo. We compared the effects of OCT1002 and the three clinically approved drugs on tumor growth and vasculature using the DSF window chamber assay ( Figure 2 ). As was observed using the dorsal tumors, a single dose of OCT1002 (30 mg/kg; administered on day 1), demonstrated similar tumor growth control to both cabazitaxel and docetaxel (Figures 2A and 2B) . Abiraterone was again the most effective in controlling tumor enlargement in the window chamber.
As for tumor vasculature, all drugs demonstrated a significant effect compared to vehicle-treated tumors at various time intervals following dosing ( Figures 2C and 2D ). OCT1002 resulted in significantly reduced tumor vasculature density at day 14 and 21, compared to control tumors, an effect we had previously noted in LNCaP xenografted tumors. 21 In contrast, docetaxel showed a marked anti-vascular effect at day 7 and 14, but by day 21 the vasculature had with bicalutamide in DSF experiments. 13, 21, 27 It is likely that this is a consequence of the blockade of tumor cell growth, which will disrupt its capacity for pro-angiogenic signalling and hence vessel formation.
However, our previous work also demonstrated that tumor vasculature could re-establish itself eventually (after 14-21 days), even with continued dosing. We hypothesized that resistant tumor cells which survived the increased hypoxic stress caused by vascular reduction were able to promote re-growth of the tumor vasculature. This new data provides further evidence for this, in the observation that the initial inhibitory effect of docetaxel on blood vessels was abrogated by day 21, which is very similar to the effect we noted using bicalutamide OCT1002 and other standard-of-care drugs. This will enable combinations to be explored to identify the potential for additivity or even synergy in dose schedule studies.
In the current study we felt that, before progressing to further scheduling combinations, it was important to look for effects in the DSF model since we have found this model to be more sensitive and capable of showing subtler differences. Using this approach, we did observe that OCT1002 can enhance the anti-tumor effects of the three other drugs.
Abiraterone was very effective as a single agent at tumor growth inhibition in this model but nevertheless a statistically significant improvement was noted at day 7 and 14 when it was used in combination with OCT1002.
The combination was also significantly better at controlling tumor growth than OCT1002 alone at day 7-21. Similarly, combining OCT1002 with cabazitaxel was significantly better at controlling tumor growth than either treatment alone at day 7-21. Finally, combining OCT1002 with docetaxel was significantly better at controlling tumor growth than either treatment alone at day 14 and 21. When we looked at the effect of the combinations on vasculature density, the most interesting effect was for docetaxel ( Figure 5C ). At day 14 and 21, the combination showed a significant reduction of vasculature compared to either treatment alone.
At day 21, the restoration of vascular density observed with docetaxel alone was completely abrogated when combined with OCT1002. This corresponds with the inhibitory effect of the docetaxel/OCT1002 combination on tumor growth observed in this model, showing promise for this treatment combination in the clinic for CRPC. Indeed, the low toxicity of OCT1002 and its mode of action may help address issues of polypharmy and toxicity associated with treatment of metastatic CRPC patients 41 by allowing lower doses of standard chemotherapy drugs to be potentially used.
Overall, our results demonstrate that OCT1002 has potential for treating CRPC. Further work is now needed to probe the specific effects of OCT1002 at a molecular and cellular level, as well as optimizing the dosing and scheduling of OCT1002 as a single agent or in combination with other drugs. Furthermore, it is now clear that a wide molecular diversity exists in human prostate tumors. 42 Understanding the complexities of this diversity is important for patient stratification as different sub-types of prostate cancer exist, each with different druggable pathways which may be potentially targeted. 42, 43 In OCT1002, we have an agent that when activated inhibits topoisomerase II, 24 a critical player in DNA replication, DNA repair and AR signalling, 44 therefore impacting upon targets that are important in driving prostate cancer. It therefore shows considerable promise as a novel precision therapy for prostate cancer.
| CONCLUSIONS
In conclusion, we have shown that OCT1002 can control the growth of CRPC xenografted PC3 tumors, in a similar way to that observed in androgen-sensitive LNCaP tumors. At a single dose of OCT1002 the effects compared favorably to the multiple dosing schedules of abiraterone, cabazitaxel, and docetaxel in these prostate cancer models. Our DSF studies showed the promise of using OCT1002 in combination with other drugs to inhibit tumor growth and significantly diminish tumor vasculature density. Together, our results provide the first evidence for the potential for OCT1002 to improve treatment responses in CRPC, especially where it is shown that patient tumors are hypoxic, a feature which is widely reported for this tumor type.
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